For Pharma

For Oncologists

Colorectal Cancer

Pancreatic Cancer



Encapsulate LLC

About Encapsulate: “Encapsulate produces automated tumor-on-a-chip systems that can grow patients’ cancer cells outside the body, and test the efficacy of chemotherapeutic drugs against them to advocate for the best course of treatment. With this technology, the oncologist can choose the most effective chemotherapy drug prior to treatment on an individualized basis.

Founder/CEO: Armin Tahmasbi Rad, Ph.D., ’19 (ENG)  Encapsulate co-founder and CEO

UConn Students assisting summer 2021:

Every year, we have had the privilege to work with UConn’s most talented students from the School of Pharmacy, School of Engineering, and School of Business. I truly enjoyed how our two interns from the School of Pharmacy, Saba and Roxanna, brought their pharmaceutical knowledge and expertise and contributed to our product development significantly.” Armin Tahmasbi Rad

“My work at Encapsulate has been a combination of both my pharmaceutical background and the technology that Dr. Rad had developed here. The Tumor on the Chip technology can be successfully used for many improvements in Oncological patient care. I wanted to take that idea and use the technology to work with different drug concentrations and visually see how effective they are. What is amazing is that the patient samples allow us to possibly provide individualized treatment plans for the future with some proof that the treatment will work.” – Saba Azam

Saba Azam (Pharm.D. candidate, 2023)

“While working with the team at Encapsulate, I have been assisting in innovating a tumor on a chip device that will test different drugs or chemotherapeutics on real patient tumor cells to examine their efficacy on its metastasis. This will give beneficial information to cancer patients and oncologists on more optimal therapies personalized to their tumor cells prior to administering them. One of my favorite aspects of working with Encapsulate this summer is knowing that the work I am involved in now could potentially be making a direct positive impact on patient care and their survival rates in the future.” – Roxanna Monshi

Roxanna Monshi (Pharm.D. candidate, 2023)

Find more about this article at: